Replies to post #40 on China Biologic Products, Inc. (CBPO)

[abh3vt]

The older 2006 warrants were called in, but there were some new warrants issued as part of the 2009 convert deal. I can't claim to know what the charges will be, but in general, as the stock price rises in any quarter, the cost of the non-cash derivative charges increases.

I expect that there will be charges for the converts as well as the warrants. I would also recommend backing them out from the income statement, as they have no impact on cash flow are merely an accounting convention. Hopefully this will be clearly spelled out in the PR to come.